Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a …

T Ciuleanu, L Stelmakh, S Cicenas, S Miliauskas… - The lancet …, 2012 - thelancet.com
Background Erlotinib, docetaxel, and pemetrexed are approved for the second-line
treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large …
被引用次数：487 相关文章

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a …

T Ciuleanu, L Stelmakh, S Cicenas, S Miliauskas… - The Lancet …, 2012 - infona.pl
Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-
small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are …

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A …

T Ciuleanu, L Stelmakh, S Cicenas, S Miliauskas… - The Lancet …, 2012 - elibrary.ru
We thank all of the patients, investigators, and members of TITAN who participated in this
study, the central laboratories that did the biomarker testing, Targos molecular pathology …

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a …

T Ciuleanu, L Stelmakh, S Cicenas… - The Lancet …, 2012 - thelancet.com
Background Erlotinib, docetaxel, and pemetrexed are approved for the second-line
treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large …
[PDF] academia.edu

[PDF][PDF] Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN) …

T Ciuleanu, L Stelmakh, S Cicenas, S Miliauskas… - Lancet Oncol, 2012 - academia.edu
Background Erlotinib, docetaxel, and pemetrexed are approved for the second-line
treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large …

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a …

T Ciuleanu, L Stelmakh, S Cicenas… - The Lancet …, 2012 - pubmed.ncbi.nlm.nih.gov
Background Erlotinib, docetaxel, and pemetrexed are approved for the second-line
treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large …

[引用][C] Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN) …

T Ciuleanu, L Stelmakh, S Cicenas, S Miliauskas… - The Lancet …, 2012 - cir.nii.ac.jp
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with
advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre …

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a …

T Ciuleanu, L Stelmakh, S Cicenas, S Miliauskas… - The Lancet …, 2012 - Elsevier
BACKGROUND: Erlotinib, docetaxel, and pemetrexed are approved for the second-line
treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large …

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a …

T Ciuleanu, L Stelmakh, S Cicenas… - The Lancet …, 2012 - europepmc.org
Background Erlotinib, docetaxel, and pemetrexed are approved for the second-line
treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large …

[引用][C] Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN) …

T Ciuleanu, L Stelmakh, S Cicenas, S Miliauskas… - Lancet …, 2012 - Elsevier Limited